Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
Frontiers in Bioengineering and Biotechnology · 22.05.2023 · 11
DOI: 10.3389/fbioe.2023.1190637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 22.05.2023. Verfasst von Xingfeng He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Introduction
Most advanced colorectal cancers are aggressive, and there is a lack of effective methods for selecting appropriate anticancer regimens. Patient-derived organoids (PDOs) have emerged as preclinical platforms for modeling clinical responses to cancer therapy.
Methods
In this study, we successfully constructed a living biobank with 42 organoids derived from primary and metastatic lesions of metastatic colorectal cancer patients. Tumor tissue was obtained from patients undergoing surgical resection of the primary or metastatic lesion and then used to establish PDOs. Immunohistochemistry (IHC) and drug sensitivity assays were performed to analyze the properties of these organoids.
Results
The mCRC organoids were successfully established with an 80% success rate. The PDOs maintained the genetic and phenotypic heterogeneity of their parental tumors. The IC50 values of5-fluorouracil (5-FU), oxaliplatin, and irinotecan (CPT11) were determined for mCRC organoids using drug sensitivity assays. The in vitro chemosensitivity data revealed the potential value of PDOs for clinical applications in predicting chemotherapy response and clinical outcomes in mCRC patients.
Discussion
In summary, the PDO model is an effective platform for in vitro assessment of patient-specific drug sensitivity, which can guide personalized treatment decisions for patients with end-stage CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Nursing Administration, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
He, X., Jiang, Y., Zhang, L., Li, Y., Hu, X., Hua, G., Cai, S., Mo, S., & Peng, J. (2023). Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1190637
Vancouver
He X, Jiang Y, Zhang L, Li Y, Hu X, Hua G, et al. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. Frontiers in Bioengineering and Biotechnology. 2023;11. doi:10.3389/fbioe.2023.1190637
BibTeX
@article{He2023,
author = {He, Xingfeng and Jiang, Yan and Zhang, Long and Li, Yaqi and Hu, Xiang and Hua, Guoqiang and Cai, Sanjun and Mo, Shaobo and Peng, Junjie},
title = {Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2023},
volume = {11},
doi = {10.3389/fbioe.2023.1190637}
}
EUVIMED